Agenus Inc. (NASDAQ:AGEN - Get Free Report) has received a consensus recommendation of "Hold" from the six ratings firms that are covering the stock, Marketbeat.com reports. Five analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $10.00.
Separately, HC Wainwright reissued a "neutral" rating on shares of Agenus in a research note on Thursday, December 5th.
View Our Latest Analysis on Agenus
Hedge Funds Weigh In On Agenus
Institutional investors have recently made changes to their positions in the stock. Point72 DIFC Ltd bought a new stake in Agenus in the 2nd quarter valued at about $51,000. EP Wealth Advisors LLC acquired a new stake in Agenus in the third quarter valued at approximately $55,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Agenus during the second quarter valued at approximately $106,000. HighTower Advisors LLC raised its position in shares of Agenus by 46.1% during the third quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company's stock worth $122,000 after purchasing an additional 7,530 shares during the period. Finally, Exchange Traded Concepts LLC lifted its holdings in shares of Agenus by 52.0% in the 3rd quarter. Exchange Traded Concepts LLC now owns 27,543 shares of the biotechnology company's stock worth $151,000 after purchasing an additional 9,422 shares in the last quarter. Institutional investors and hedge funds own 61.46% of the company's stock.
Agenus Stock Performance
Shares of NASDAQ AGEN traded down $0.28 during midday trading on Friday, reaching $3.12. The stock had a trading volume of 294,304 shares, compared to its average volume of 445,068. The company's 50 day moving average price is $3.22 and its 200 day moving average price is $5.83. Agenus has a twelve month low of $2.50 and a twelve month high of $19.69. The firm has a market cap of $73.19 million, a price-to-earnings ratio of -0.28 and a beta of 1.27.
Agenus Company Profile
(
Get Free ReportAgenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Further Reading
Before you consider Agenus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agenus wasn't on the list.
While Agenus currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for February 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
